Densema Gomboeva

Ms. Densema Gomboeva

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2024 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
MNM.A. Nikitina
M.A. Nikitina
EBElena Yu. Bragina
Elena Yu. Bragina
NMNazarenko Maria
Nazarenko Maria
LLLyudmila Levchuk
Lyudmila Levchuk
SISvetlana Ivanova
Svetlana Ivanova
VAV.M. Alifirova
V.M. Alifirova
OBJECTIVE To evaluate the clinical features and the level of serum brain-derived neurotrophic factor (BDNF) in groups of patients with Parkinson’s disease (PD) differentiated by the genotypes of BDNF polymorphism (rs6265). MATERIAL AND METHODS The level of serum BDNF in the biomarkers’ multiplex panel of neurodegenerative diseases (HNDG3MAG-36K) was assessed in 134 PD patients. Allele discrimination was carried out by real-time PCR using TaqMan probes for the analysis of BDNF rs6265 polymorphism in groups of patients and controls (n=192) matched for sex, age and ethnicity. RESULTS Comparing the distribution of rs6265 genotypes and alleles between groups of patients and controls no significant differences were found (p>0.05). Serum BDNF levels varied significantly by genotype (rs6265) among PD patients. Minimum mean serum BDNF level (320.1±164.6 pg/ml) was noted for individuals with the AA genotype, which significantly differs from the corresponding indicator among individuals with GA (2944.2±1590.6 pg/ml; p=0.0001) and GG genotypes (2949.4±1620.6 pg/ml; p=3.9×10–5). The concentration of BDNF significantly differed between patients with different forms of PD (p=0.0007) and increased as the stage of the disease progressed according to Hoehn and Yahr staging scale (p=1.0×10–6). CONCLUSION The BDNF rs6265 polymorphism was not associated with the development of PD in the studied population. The variability of the mean serum BDNF level was established depending on the genotype of the BDNF polymorphism in PD patients and a number of clinical features.

1 March 2020 in Russian Journal of Genetics
Verified
Journal Article
Closed access
PDF file
DGDensema Gomboeva
Densema Gomboeva
EBE. Yu. Bragina
E. Yu. Bragina
MNM. S. Nazarenko
M. S. Nazarenko
VPV. P. Puzyrev
V. P. Puzyrev
The simultaneous development of several diseases (comorbidity, syntropy) in particular patients is a common phenomenon in modern clinical practice. However, the results of recent epidemiological studies have pointed to the new phenomenon of inverse comorbidity (or dystropy)—that means that some diseases can occur together in one person more rarely than in other people according to frequencies of these disorders in the population as a whole. Such dystropic (inversely comorbid) diseases are Huntington’s disease and oncological ones. In this paper, we perform a review of existing information supporting the hypothesis of the oncoprotection in carriers of HTT mutation, also including features of interactions of genes and proteins in such processes as autophagy and apoptosis.

7 January 2021 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
MNM. A. Nikitina
M. A. Nikitina
EBElena Yu. Bragina
Elena Yu. Bragina
NMNazarenko Maria
Nazarenko Maria
NZN. G. Zhukova
N. G. Zhukova
DGDensema Gomboeva
Densema Gomboeva
VAV. M. Alifirova
V. M. Alifirova
Атипичное течение болезни Паркинсона с клиническими проявлениями болезни Гентингтона у пациентки с аллелем 27 CAG-повторов в гене HTT

14 January 2020 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
MNM. A. Nikitina
M. A. Nikitina
NZN. G. Zhukova
N. G. Zhukova
EBElena Yu. Bragina
Elena Yu. Bragina
VAV. M. Alifirova
V. M. Alifirova
IZI. A. Zhukova
I. A. Zhukova
IZIrina Z. Zhalsanova
Irina Z. Zhalsanova
Non-motor symptoms are an essential manifestation of the clinical picture of Parkinson's disease (PD). This literature review is devoted to the study of recent advances in the field of clinical and pathophysiological aspects of the non-motor manifestations of Parkinson's disease.Aim. The aim was to study and generalize the wide range of non-motor manifestations of PD and their features in this pathology, and to reveal the pathophysiological link between motor and non-motor manifestations of the disease and the role of the neurodegenerative process in the clinical picture of PD.Materials and methods. Keywords (Parkinson's disease, non-motor symptoms, apathy, anxiety, depression, sleep disorder, pain) search in the Web of Science, Core Collection, Scopus, Pubmed databases.Results. Knowledge about the presence of PD non-motor symptoms, characteristics of their manifestations improve their diagnosis and help to choose the correct treatment strategy. This survey comprises nonmotor manifestations of PD, such as: mood disorders (apathy, anxiety, depression), impulse control disorders (dopamine disregulation syndrome), sleep disorders (insomnia, excessive daytime sleepiness, bouts of sleepiness, conduct disorder in REM phase of sleep), autonomic disorders (constipation, enuresis, thermoregulatory dysfunction, cardiovascular disorders, orthostatic hypotension), and cognitive impairment.

7 August 2025 in Epigenomes
Verified
Journal Article
Open access
PDF file
NBNadezhda P Babushkina
Nadezhda P Babushkina
EBElena Yu. Bragina
Elena Yu. Bragina
DGDensema Gomboeva
Densema Gomboeva
Iuliia A. KorolevaIuliia A. Koroleva
Iuliia A. Koroleva
SISergey Illarioshkin
Sergey Illarioshkin
VPValery P. Puzyrev
Valery P. Puzyrev
Background. Studies of comorbid (syntropic) and inversely comorbid (rarely occurring together, i.e., dystropic) diseases have focused on the search for molecular causes of this phenomenon. Materials. We investigated DNA methylation levels in regulatory regions of 23 apoptosis-associated genes as candidate loci associated with the “cancer–neurodegeneration” dystropy in patients with Huntington’s disease (HD) and patients with non–small cell lung cancer (LC). Results. Statistically significant differences in methylation levels between the HD and LC groups were found for 41 CpG sites in 16 genes. The results show that five genes (SETDB1, TWIST1, HDAC1, SP1, and GRIA2) are probably involved in the phenomenon of inverse comorbidity of these diseases. For these genes, the methylation levels of the studied CpG sites were altered in opposite directions in the two groups of patients, compared to the control group. Conclusions. For the SP1 gene, the above hypothesis is supported by our analysis of open-access data on gene expression in patients with the aforementioned diagnoses and fits a probable mechanism of the “HD–LC” dystropy.

29 December 2022 in Acta Biomedica Scientifica
Verified
Journal Article
Open access
PDF file
NBNadezhda P Babushkina
Nadezhda P Babushkina
MNM. A. Nikitina
M. A. Nikitina
EBElena Yu. Bragina
Elena Yu. Bragina
VAV. M. Alifirova
V. M. Alifirova
АПА. Е. Постригань
А. Е. Постригань
NMNazarenko Maria
Nazarenko Maria
Background. Approximately 5–10 % of cases of Parkinson’s disease (PD) are monogenic, in other cases the pathology has a multifactorial etiology. One of recognized pathogenetic pathways of PD is mitochondrial dysfunction, in particular the accumulation of damage in mitochondrial DNA. Hence, the genes of DNA repair proteins are promising candidate genes for multifactorial forms of PD.The aim. To study the involvement of genes of DNA repair proteins in the development of Parkinson’s disease.Materials and methods. The associative analysis was carried out while comparing a group of patients with PD (n = 133) with a Tomsk population sample (n = 344). SNaPshot analysis was used to study 8 SNPs in genes of DNA repair proteins (rs560191 (TP53BP1); rs1805800 and rs709816 (NBN); rs473297 (MRE11A); rs1189037 and rs1801516 (ATM); rs1799977 (MLH1); rs1805321 (PMS2)).Results. Common alleles and homozygous rs1801516 genotypes in the ATM gene predispose the development of PD (odds ratio (OR) – 3.27 (p = 0.000004) and OR = 3.46 (p = 0.00008) for risk alleles and genotype respectively) and rs1799977 in the MLH1 gene (OR = 1.88 (p = 0.0004) and OR = 2.42 (p = 0.00007) respectively); heterozygotes have a protective effect (OR = 0.33 (p = 0.0007) and OR = 0.46 (p = 0.0007) for ATM and MLH1, respectively). The rare rs1805800 allele in the NBN gene (OR = 1.62 (p = 0.019)) and a homozygous genotype for it (OR = 2.28 (p = 0.016)) also predispose to PD. Associations with PD of the ATM, MLH1, NBN genes were revealed for the first time.Conclusion. Mitochondrial dysfunction is one of the key factors in the pathogenesis of PD, while at least two of the three protein products of associated genes are involved in the development of mitochondrial dysfunction. Accordingly, it can be assumed that associated genes are involved in the pathogenesis of PD precisely through mitochondrial dysfunction.